We use our unique microRNA-based biomarkers to personalize cancer treatments and drug development.
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation therapy, surgery, and/or hormone therapy Radiation has […]Read More
For COVID-19 testing, there are two predominant tests on the market: viral tests and serum antibody tests. Let’s take a look at the main differences between these two types of tests, like what they look for, when each is the most effective, and the logistics of providing each type. 1. Viral Tests Viral, or PCR, tests determine if an individual […]Read More
CLIA Lab Address: